CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 310,463	$ 331,339	$ 391,866
Expenses:
Selling, general and administrative	98,232	63,538	16,187
Research and development	33,922	41,432	576
Amortization of acquired intangible assets	21,784	5,581	0
Gain on sale of Theravance Respiratory Company, LLC ("TRC")	0	(266,696)	0
Loss on extinguishment of debt	0	20,662	0
Changes in fair values of equity method investments, net	(77,392)	161,749	(84,392)
Changes in fair value of equity and long-term investments, net	(11,129)	(8,462)	(6,638)
Interest and dividend income	(15,818)	(6,369)	(1,839)
Interest expense	19,157	15,789	19,070
Other expense, net	4,969	3,373	3,626
Total expenses, net	116,365	44,390	(53,410)
Income before income taxes	194,098	286,949	445,276
Income tax expense, net	14,376	66,687	76,439
Net income	179,722	220,262	368,837
Net loss attributable to noncontrolling interests	0	6,341	102,983
Net income attributable to Innoviva stockholders	$ 179,722	$ 213,921	$ 265,854
Basic net income per share attributable to Innoviva stockholders	$ 2.75	$ 3.07	$ 3.24
Diluted net income per share attributable to Innoviva stockholders	$ 2.2	$ 2.37	$ 2.87
Shares used to compute Innoviva basic and diluted net income per share:
Shares used to compute basic net income per share	65,435	69,644	82,062
Shares used to compute diluted net income per share	86,876	95,248	94,310
Royalty revenue
Revenue:
Total revenue	$ 238,846	$ 311,645	$ 391,866
Net product sales
Revenue:
Total revenue	60,617	19,694	0
Expenses:
Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding amortization of intangible assets)	41,040	13,793	0
License revenue
Revenue:
Total revenue	11,000	0	0
License
Expenses:
Cost of license revenue	$ 1,600	$ 0	$ 0